AbCellera Biologics Inc. | Small-cap | Healthcare
$5.53
-6.43%
| AbCellera Biologics Stock Comparison:
AbCellera Biologics vs VertexAbCellera Biologics vs AlnylamAbCellera Biologics vs Vera TherapeuticsAbCellera Biologics vs ViridianAbCellera Biologics vs Celldex TherapeuticsAbCellera Biologics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 4.2M
Operating Income -58.5M -1,381.51%
Net Income -45.6M -1,077.24%
EPS (Diluted) $-0.15

Balance Sheet Metrics

Total Assets 1.3B
Total Liabilities 321.2M
Shareholders Equity 1.0B
Debt to Equity 0.31

Cash Flow Metrics

Operating Cash Flow -7.1M
Free Cash Flow -22.2M

Revenue & Profitability Trend

AbCellera Biologics Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue i 28.8M 38.0M 485.4M 375.2M 233.2M
Cost of Goods Sold i 0 0 66.4M 45.5M 27.1M
Gross Profit i 28.8M 38.0M 419.0M 329.7M 206.0M
Gross Margin % i 100.0% 100.0% 86.3% 87.9% 88.4%
Operating Expenses
Research & Development i 167.3M 175.7M 107.9M 62.1M 29.4M
Selling, General & Administrative i 85.5M 75.2M 66.8M 48.8M 15.8M
Other Operating Expenses i -13.6M -14.2M -10.6M -17.5M -8.3M
Total Operating Expenses i 239.1M 236.7M 164.1M 93.3M 36.8M
Operating Income i -301.1M -223.1M 227.1M 221.9M 164.4M
Operating Margin % i -1,044.4% -586.6% 46.8% 59.1% 70.5%
Non-Operating Items
Interest Income i 38.5M 42.2M 16.1M 3.3M 293.0K
Interest Expense i - - 4.0M 5.2M 6.5M
Other Non-Operating Income 62.3M 6.8M -4.0M -6.1M -300.0K
Pre-tax Income i -200.4M -174.0M 239.1M 219.1M 157.8M
Income Tax i -37.5M -27.6M 80.6M 65.7M 38.9M
Effective Tax Rate % i 0.0% 0.0% 33.7% 30.0% 24.7%
Net Income i -162.9M -146.4M 158.5M 153.5M 118.9M
Net Margin % i -564.8% -385.0% 32.7% 40.9% 51.0%
Key Metrics
EBITDA i -204.1M -192.2M 260.2M 239.1M 169.9M
EPS (Basic) i $-0.55 $-0.51 $0.56 $0.56 $0.53
EPS (Diluted) i $-0.55 $-0.51 $0.50 $0.48 $0.45
Basic Shares Outstanding i 294327532 289166486 285056606 275763745 159195023
Diluted Shares Outstanding i 294327532 289166486 285056606 275763745 159195023

Income Statement Trend

AbCellera Biologics Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets
Cash & Equivalents i 156.3M 133.3M 386.5M 476.1M 594.1M
Short-term Investments i 469.3M 627.3M 500.0M 246.8M 0
Accounts Receivable i 33.6M 30.6M 38.6M 160.6M 213.2M
Inventory i - 1.1M 1.5M 1.7M 1.4M
Other Current Assets 8.6M 20.9M 9.1M - -
Total Current Assets i 751.4M 872.0M 1.0B 929.8M 813.3M
Non-Current Assets
Property, Plant & Equipment i 150.9M 143.5M 122.1M 56.6M 13.5M
Goodwill i 137.7M 216.0M 227.1M 244.0M 178.2M
Intangible Assets i 42.1M 120.4M 131.5M 148.4M 115.2M
Long-term Investments - - - - -
Other Non-Current Assets 96.5M 94.2M 46.3M 38.0M 14.3M
Total Non-Current Assets i 609.2M 616.1M 515.4M 388.8M 192.2M
Total Assets i 1.4B 1.5B 1.5B 1.3B 1.0B
Liabilities
Current Liabilities
Accounts Payable i 34.4M 25.5M 14.8M 14.9M 7.3M
Short-term Debt i 4.6M 6.2M 5.6M 3.7M 675.0K
Current Portion of Long-term Debt - - - - -
Other Current Liabilities - - - 4.9M 9.3M
Total Current Liabilities i 76.6M 119.0M 118.3M 120.7M 103.5M
Non-Current Liabilities
Long-term Debt i 60.7M 71.2M 76.7M 36.4M 3.7M
Deferred Tax Liabilities i 10.1M 30.6M 33.2M 37.4M 26.2M
Other Non-Current Liabilities 1.5M 5.9M 3.1M 1.7M 6.6M
Total Non-Current Liabilities i 227.9M 216.8M 189.3M 172.2M 71.5M
Total Liabilities i 304.5M 335.8M 307.6M 292.8M 175.0M
Equity
Common Stock i 777.2M 753.2M 734.4M 722.4M 710.4M
Retained Earnings i 116.9M 279.8M 426.2M 267.7M 114.2M
Treasury Stock i - - - - -
Other Equity - - - - -
Total Shareholders Equity i 1.1B 1.2B 1.2B 1.0B 830.5M
Key Metrics
Total Debt i 65.4M 77.4M 82.3M 40.1M 4.4M
Working Capital i 674.8M 753.0M 907.2M 809.1M 709.8M

Balance Sheet Composition

AbCellera Biologics Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income i -162.9M -146.4M 158.5M 153.5M 118.9M
Depreciation & Amortization i 97.0M 30.9M 33.1M 17.2M 5.3M
Stock-Based Compensation i 67.6M 64.2M 49.5M 30.6M 8.4M
Working Capital Changes i -36.5M 13.2M 26.8M 40.9M -180.3M
Operating Cash Flow i -119.2M -43.9M 274.3M 243.8M -40.9M
Investing Activities
Capital Expenditures i -78.4M -76.9M -70.7M -58.5M -9.7M
Acquisitions i -19.6M -13.7M -25.7M -41.8M -106.9M
Investment Purchases i -765.1M -1.1B -781.4M -292.2M 0
Investment Sales i 948.8M 910.9M 510.6M 27.6M 0
Investing Cash Flow i 121.4M -220.5M -350.6M -332.2M -114.8M
Financing Activities
Share Repurchases i - - - - 0
Dividends Paid i - - - - -
Debt Issuance i - 11.6M 2.8M 5.5M 105.5M
Debt Repayment i - - -323.0K -1.8M -19.9M
Financing Cash Flow i 12.8M 10.4M -2.0M -5.7M 682.7M
Free Cash Flow i -187.0M -121.4M 204.7M 186.1M 8.0M
Net Change in Cash i 15.0M -254.1M -78.3M -94.2M 527.0M

Cash Flow Trend

AbCellera Biologics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -11.23
Forward P/E -8.74
Price to Book 1.69
Price to Sales 52.45
PEG Ratio 1.46

Profitability Ratios

Profit Margin 100.00%
Operating Margin -290.24%
Return on Equity -15.64%
Return on Assets -10.96%

Financial Health

Current Ratio 11.07
Debt to Equity 14.11
Beta 0.69

Per Share Data

EPS (TTM) $-0.56
Book Value per Share $3.41
Revenue per Share $0.11

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
abcl 1.7B -11.23 1.69 -15.64% 100.00% 14.11
Vertex 108.0B 29.16 6.12 22.77% 31.86% 8.89
Alnylam 60.2B -209.88 240.24 -257.83% -12.96% 1,093.31
Vera Therapeutics 2.0B -11.10 4.20 -54.84% 0.00% 16.56
Viridian 1.7B -7.18 5.35 -65.88% 0.00% 4.48
Celldex Therapeutics 1.7B -11.03 2.66 -27.18% 0.00% 0.46

Financial data is updated regularly. All figures are in the company's reporting currency.